SCHEMBL19600503

SCHEMBL19600503

CN1CCN(Cc2cccc(OC=O)n2)CCN(Cc2ccc(N=C=S)cc2)CCN(Cc2cccc(C(=O)O)n2)CC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 2/20 0.35
HDAC3 O15379 1/20 0.35
HDAC4 P56524 1/20 0.35
HDAC1 Q13547 1/20 0.35
HDAC7 Q8WUI4 1/20 0.35
HDAC2 Q92769 1/20 0.35
HDAC10 Q969S8 1/20 0.35
HDAC11 Q96DB2 1/20 0.35
HDAC8 Q9BY41 1/20 0.35
HDAC9 Q9UKV0 1/20 0.35
HDAC5 Q9UQL6 1/20 0.35
TP53 P04637 2/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
MC4R P32245 1/20 0.34
PARP1 P09874 2/20 0.34
PARP2 Q9UGN5 1/20 0.34
PARP3 Q9Y6F1 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29556200 0.90 MC4R (0.41) HDAC6HDAC3HDAC4HDAC1HDAC7
SCHEMBL17797163 0.90 MC4R (0.41) HDAC6HDAC3HDAC4HDAC1HDAC7
SCHEMBL19600511 0.86 MC4R (0.38) HDAC6HDAC3HDAC4HDAC1HDAC7
SCHEMBL19600508 0.80 ALDH1A1 (0.37) CYP2D6CNR1
SCHEMBL26241433 0.77 CXCR4 (0.40) NPC1RAB9ACNR1MRGPRX4
SCHEMBL30577958 0.75 MC4R (0.46) MC4RCHRM1CNR1MRGPRX4
SCHEMBL17805278 0.75 MC4R (0.46) MC4RCHRM1CNR1MRGPRX4
SCHEMBL1252458 0.75 MC4R (0.46) MC4RCHRM1CNR1MRGPRX4
SCHEMBL18110284 0.75 CYP2D6 (0.43) TP53CYP1A2CYP3A4CYP2D6ALOX12
SCHEMBL18110236 0.75 CYP2D6 (0.43) TP53CYP1A2CYP3A4CYP2D6ALOX12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170326261-A1 BIFUNCTIONAL do2pa DERIVATIVES, CHELATES WITH METALLIC CATIONS AND USE THEREOF CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2017-11-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170326261-A1 BIFUNCTIONAL do2pa DERIVATIVES, CHELATES WITH METALLIC CATIONS AND USE THEREOF AP2A2, ATP2A2, SLC20A2 HDAC6 2760/4885HDAC3 2735/4885HDAC4 2825/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.